Potential Biomarkers for NSAID-Exacerbated Respiratory Disease
- PMID: 28852271
- PMCID: PMC5568600
- DOI: 10.1155/2017/8160148
Potential Biomarkers for NSAID-Exacerbated Respiratory Disease
Abstract
Asthma is a common chronic disease with several variant phenotypes and endotypes. NSAID-exacerbated respiratory disease (NERD) is one such endotype characterized by asthma, chronic rhinosinusitis (CRS) with nasal polyps, and hypersensitivity to aspirin/cyclooxygenase-1 inhibitors. NERD is more associated with severe asthma than other asthma phenotypes. Regarding diagnosis, aspirin challenge tests via the oral or bronchial route are a standard diagnostic method; reliable in vitro diagnostic tests are not available. Recent studies have reported various biomarkers of phenotype, diagnosis, and prognosis. In this review, we summarized the known potential biomarkers of NERD that are distinct from those of aspirin-tolerant asthma. We also provided an overview of the different NERD subgroups.
Similar articles
-
Nonsteroidal anti-inflammatory drug (NSAID) exacerbated respiratory disease phenotype: Topical NSAID and asthma control - A possible oversight link.Respir Med. 2016 Sep;118:1-3. doi: 10.1016/j.rmed.2016.07.004. Epub 2016 Jul 9. Respir Med. 2016. PMID: 27578463
-
From "Samter's Triad" to "NERD": The Long and Winding Road to Understanding Aspirin-Exacerbated Respiratory Disease.Immunol Allergy Clin North Am. 2016 Nov;36(4):xiii-xiv. doi: 10.1016/j.iac.2016.08.002. Immunol Allergy Clin North Am. 2016. PMID: 27712770 No abstract available.
-
Nonsteroidal anti-inflammatory drugs-exacerbated respiratory disease in adolescents.Int Forum Allergy Rhinol. 2015 May;5(5):392-8. doi: 10.1002/alr.21494. Epub 2015 Mar 6. Int Forum Allergy Rhinol. 2015. PMID: 25755210
-
Nonsteroidal anti-inflammatory drug-exacerbated respiratory disease: diagnosis and current management.Pol Arch Intern Med. 2023 Sep 29;133(9):16544. doi: 10.20452/pamw.16544. Epub 2023 Aug 7. Pol Arch Intern Med. 2023. PMID: 37548592 Review.
-
Current Goals of NSAID-ERD Management: Patient-Centered Approaches Involving NSAID Desensitization With and Without Biologics.J Allergy Clin Immunol Pract. 2024 Nov;12(11):2934-2944. doi: 10.1016/j.jaip.2024.09.012. Epub 2024 Sep 19. J Allergy Clin Immunol Pract. 2024. PMID: 39306329 Review.
Cited by
-
New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis.Clin Sci (Lond). 2023 May 18;137(9):727-753. doi: 10.1042/CS20190281. Clin Sci (Lond). 2023. PMID: 37199256 Free PMC article. Review.
-
Immune Metabolism in TH2 Responses: New Opportunities to Improve Allergy Treatment - Disease-Specific Findings (Part 1).Curr Allergy Asthma Rep. 2023 Jan;23(1):29-40. doi: 10.1007/s11882-022-01057-8. Epub 2022 Nov 28. Curr Allergy Asthma Rep. 2023. PMID: 36441389 Free PMC article. Review.
-
Immunologic Basis of Type 2 Biologics for Severe Asthma.Immune Netw. 2022 Dec 5;22(6):e45. doi: 10.4110/in.2022.22.e45. eCollection 2022 Dec. Immune Netw. 2022. PMID: 36627938 Free PMC article. Review.
-
Potential Metabolic Biomarkers in Adult Asthmatics.Metabolites. 2021 Jun 30;11(7):430. doi: 10.3390/metabo11070430. Metabolites. 2021. PMID: 34209139 Free PMC article. Review.
-
Bacterial Extracellular Vesicles: A Candidate Molecule for the Diagnosis and Treatment of Allergic Diseases.Allergy Asthma Immunol Res. 2023 May;15(3):279-289. doi: 10.4168/aair.2023.15.3.279. Allergy Asthma Immunol Res. 2023. PMID: 37188485 Free PMC article. Review.
References
-
- Samter M., Beers R. F. Intolerance to aspirin: clinical studies and consideration of its pathogenesis. Annals of Internal Medicine. 1968;68(5):975–983. - PubMed
-
- E. S. Group. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Respiratory Journal. 2003;22(3):470–477. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources